Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients. Methods: Results of 9720 were compared with results from similar patient populations treated on 3 other CALGB trials ...
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback